Vergnon J M, Vincent M, Ros A, Brun Y, Brune J
Rev Pneumol Clin. 1985;41(3):205-11.
This study involved an open trial with parallel randomised series receiving either cefoperazone (2 g/d) or a combination of ampicillin (6 g/d) and tobramycin (3 to 4 mg/kg/d). The 30 patients included were of both sexes (male predominance), hospitalised, aged 62 +/- 11,5 years and suffering from a severe bronchopulmonary or pleural infection. Underlying pathology was serious (neoplasm, C.O.D.L., bronchiectasis, cardiac pathology). No significant difference was seen in the sampling of the two populations. Cefoperazone was prescribed in 2 infusions per 24 hours. Ampicillin was given as 3 infusions, followed by tobramycin administered by a similar number of injections. The duration of treatment was 16.8 +/- 9 days (cefoperazone) and 11,8 +/- 6,5 days (ampicillin + tobramycin). Overall evaluation (clinical, radiological and laboratory criteria) showed 88% (cefoperazone group) and 71% (ampicillin + tobramycin group) recovery and improvement rates. There were two failures in the cefoperazone group and 6 failures in the other group. These results were not statistically different. Three of the 6 failures could be attributed to resistance of the initial bacteria or selected by one or other type of treatment. None of the antibiotics prescribed raised any acceptability problems.
本研究为一项开放试验，采用平行随机分组，一组接受头孢哌酮（2克/天），另一组接受氨苄西林（6克/天）与妥布霉素（3至4毫克/千克/天）的联合用药。纳入的30例患者男女皆有（男性居多），均为住院患者，年龄62±11.5岁，患有严重支气管肺部或胸膜感染。基础病理情况严重（肿瘤、慢性阻塞性肺疾病、支气管扩张、心脏疾病）。两组患者的样本情况无显著差异。头孢哌酮每24小时分2次输注给药。氨苄西林分3次输注给药，随后妥布霉素以相似次数注射给药。治疗时长为头孢哌酮组16.8±9天，氨苄西林+妥布霉素组11.8±6.5天。综合评估（临床、影像学和实验室标准）显示，头孢哌酮组的康复和改善率为88%，氨苄西林+妥布霉素组为71%。头孢哌酮组有2例治疗失败，另一组有6例治疗失败。这些结果无统计学差异。6例治疗失败中有3例可归因于初始细菌耐药或因一种或另一种治疗方式导致。所使用的任何一种抗生素均未出现可接受性问题。
